{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:47:08Z","timestamp":1781750828675,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T00:00:00Z","timestamp":1244592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Defects of antibody production are the most common of the primary immune defects of man. While these defects have been described in clinical terms for more than five decades, in most cases, the pathogenesis is still poorly understood. The most common clinically important of these is common variable immune deficiency. However there is no strict definition of this defect and the criteria for initiating immune globulin therapy are not standardized, leading to wide variation in treatment practices. In addition there has been no clear means to adequate assess progression of lung disease or elucidate the causes of progressive pulmonary inflammation found in some subjects. Moreover, there are still questions such as what are the best predictors of chronic lung disease and how can we prevent this disorder. Other complications such as autoimmunity, granulomatous disease, gastrointestinal inflation, are similarly poorly understood although treatment with various biological agents has been used with some success. A few bio-markers for assessing clinical and immunologic status have been proposed, and some have proved to be useful, but additional methods to gauge the benefits of therapy, predict outcomes, and harmonize treatment practices are needed. Aside from Ig replacement, additional means of prevention of lung disease may need consideration to reduce lung damage apart from prophylactic antibiotics. These might include using macrolides as anti-inflammatory agents, inhaled corticosteroids, bronchodilators, mucolytics or mechanical or rehabilitative respiratory methods.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2009.03952.x","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T10:59:33Z","timestamp":1244631573000},"page":"12-16","source":"Crossref","is-referenced-by-count":21,"title":["Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency"],"prefix":"10.1093","volume":"157","author":[{"given":"C","family":"Cunningham-Rundles","sequence":"first","affiliation":[{"name":"Mount Sinai School of Medicine, New York City, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"2021122708533284300_b1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1067\/mai.2002.124999","article-title":"Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency","volume":"109","author":"Busse","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708533284300_b2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10875-007-9169-9","article-title":"Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration","volume":"28","author":"Quinti","year":"2008","journal-title":"J Clin Immunol"},{"key":"2021122708533284300_b3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/00006454-199711000-00007","article-title":"Efficacy of a two-component acellular pertussis vaccine in infants","volume":"16","author":"Liese","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"2021122708533284300_b4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","article-title":"Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients","volume":"134","author":"Quartier","year":"1999","journal-title":"J Pediatr"},{"key":"2021122708533284300_b5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/00365540600951192","article-title":"Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up","volume":"39","author":"Olinder-Nielsen","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2021122708533284300_b6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70085-0","article-title":"Pulmonary abnormalities in patients with primary hypogammaglobulinemia","volume":"104","author":"Kainulainen","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708533284300_b7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/ajrccm.159.4.9807067","article-title":"Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia","volume":"159","author":"Kainulainen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122708533284300_b8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J Clin Immunol"},{"key":"2021122708533284300_b9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"2021122708533284300_b10","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708533284300_b11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"2021122708533284300_b12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.intimp.2004.02.011","article-title":"Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency","volume":"4","author":"De Gracia","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"2021122708533284300_b13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clim.2008.02.013","article-title":"Memory B cells in common variable immunodeficiency: clinical associations and sex differences","volume":"128","author":"Sanchez-Ramon","year":"2008","journal-title":"Clin Immunol"},{"key":"2021122708533284300_b14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"2021122708533284300_b15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11882-001-0027-1","article-title":"Common variable immunodeficiency","volume":"1","author":"Cunningham-Rundles","year":"2001","journal-title":"Curr Allergy Asthma Rep"},{"key":"2021122708533284300_b16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaci.2004.10.048","article-title":"The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency","volume":"115","author":"Carsetti","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"2021122708533284300_b17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: defining subgroups in common variable immunodeficiency","volume":"111","author":"Wehr","year":"2008","journal-title":"Blood"},{"key":"2021122708533284300_b18","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann","year":"1969","journal-title":"Prog Allergy"},{"key":"2021122708533284300_b19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1423-0410.2003.00286.x","article-title":"Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%)","volume":"84","author":"Ballow","year":"2003","journal-title":"Vox Sang"},{"key":"2021122708533284300_b20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10875-007-9096-9","article-title":"Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases","volume":"27","author":"Berger","year":"2007","journal-title":"J Clin Immunol"},{"key":"2021122708533284300_b21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","article-title":"Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases","volume":"24","author":"Ochs","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021122708533284300_b22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-007-9107-x","article-title":"A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma","volume":"27","author":"Berger","year":"2007","journal-title":"J Clin Immunol"},{"key":"2021122708533284300_b23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2021122708533284300_b24","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.179.7.4580","article-title":"Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism","volume":"179","author":"Akilesh","year":"2007","journal-title":"J Immunol"},{"key":"2021122708533284300_b25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","article-title":"A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter","volume":"119","author":"Sachs","year":"2006","journal-title":"Immunology"},{"key":"2021122708533284300_b26","first-page":"1158","article-title":"Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations","volume":"11","author":"Mikolajczyk","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"2021122708533284300_b27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/187152808786848414","article-title":"Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back","volume":"7","author":"Vanaudenaerde","year":"2008","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2021122708533284300_b28","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001288.pub3","article-title":"Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease","volume":"1","author":"Walters","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2021122708533284300_b29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.rmed.2008.10.014","article-title":"Improving mucociliary clearance in chronic obstructive pulmonary disease","volume":"103","author":"Bhowmik","year":"2009","journal-title":"Respir Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2009.03952.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/Supplement_1\/12\/41925248\/j.1365-2249.2009.03952.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/Supplement_1\/12\/41925248\/j.1365-2249.2009.03952.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:21:46Z","timestamp":1641054106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/157\/Supplement_1\/12\/6438938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":29,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2009,6,10]]},"published-print":{"date-parts":[[2009,6,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03952.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,9]]},"published":{"date-parts":[[2009,6,10]]}}}